Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Do NSAIDs Mask MRI Findings in Patients with Axial Spondyloarthritis?

Michele B. Kaufman, PharmD, BCGP  |  Issue: September 2023  |  July 17, 2023

In all, 296 patients (95%) completed the NSAID washout and had scan 1. After the washout period, 50% of patients (n=135) reported an increase in spine pain at a median of two points on a numerical rating scale of 0–10 (interquartile range: 1–3), and 61% of patients (n=166) had worsening of disease activity, with a median BASDAI increase of 0.9 (interquartile range: 0.5–1.6).

After scan 1, 50% of patients (n=149) had bone marrow edema lesions. Of these patients, 131 (88%) participated in scan 2. Of the 131 patients who completed scan 2, 31 patients had no bone marrow edema lesions (24%; 95% confidence interval: 17–32%).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion

The study results suggest NSAIDs may affect bone marrow edema when sacroiliitis is also present. When NSAIDs were being taken by patients, an approximate 25% reduction in lesions was found.

Additionally, when NSAIDs are consumed, axSpA diagnosis and classification may be hindered. To determine a more accurate axSpA diagnosis, use of an NSAID washout period may be prudent prior to the MRI imaging, if the patient agrees.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This study is useful in garnering a more accurate diagnosis in this patient population.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Jones GT, Bennett  AN, Sengupta R, et al. Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis (abs OA14). Oral presentation, British Society for Rheumatology Annual Conference. 2023 Apr 23.
  2. Diseases and conditions: Spondyloarthritis. American College of Rheumatology. 2023.

Page: 1 2 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:AS Resource CenteraxSpAMagnetic resonance imaging (MRI)MRIsacroiliac jointssacroiliitis

Related Articles
    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    February 10, 2022

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022

    November 18, 2022

    PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…

    Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis

    May 1, 2014

    New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation

    Envision Arthritis Pathology

    April 1, 2008

    MRI advances in RA and OA

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences